Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Osimertinib

2e67fbf3-c570-5767-ac94-ac19240d1d43 · FDA Approved · targets EGFR

Osimertinib

MeasuredReference

Osimertinib targets ERBB4_HER4, ERBB2_HER2, EGFR. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

ERBB4_HER4ERBB2_HER2EGFRTXKJAK3

Top hallmarks

  • tumor promoting inflammation2.5k
  • proliferation1.9k
  • evading apoptosis1.8k

Top pathways disrupted

  • allograft rejection4.4k
  • apical junction4.4k
  • pi3k akt mtor signaling4.3k

Resistance landscape — Osimertinib

MeasuredReference

10 known oncogenic variants exist on Osimertinib's top targets — see detail for inhibition impact.

Open in new tab